CervoMed (CRVO) Competitors

I-Mab (NASDAQ:IMAB) and CervoMed (NASDAQ:CRVO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, valuation, earnings, dividends and media sentiment.

Do institutionals and insiders have more ownership in IMAB or CRVO?

38.4% of I-Mab shares are held by institutional investors. Comparatively, 25.2% of CervoMed shares are held by institutional investors. 22.1% of I-Mab shares are held by insiders. Comparatively, 35.4% of CervoMed shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Does the media favor IMAB or CRVO?

In the previous week, I-Mab and I-Mab both had 2 articles in the media. CervoMed's average media sentiment score of 1.29 beat I-Mab's score of -0.09 indicating that CervoMed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
I-Mab	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CervoMed	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is IMAB or CRVO more profitable?

I-Mab has a net margin of 0.00% compared to CervoMed's net margin of -200.57%. I-Mab's return on equity of -19.81% beat CervoMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
I-Mab	N/A	-19.81%	-18.63%
CervoMed	-200.57%	-44.07%	-40.65%

Which has stronger valuation & earnings, IMAB or CRVO?

CervoMed has higher revenue and earnings than I-Mab.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
I-Mab	$3.89M	46.18	-$22.23M	N/A	N/A
CervoMed	$9.74M	5.63	-$16.29M	-$2.18	-2.89

Do analysts recommend IMAB or CRVO?

I-Mab presently has a consensus price target of $6.00, suggesting a potential upside of 172.73%. CervoMed has a consensus price target of $22.57, suggesting a potential upside of 258.28%. Given CervoMed's higher possible upside, analysts plainly believe CervoMed is more favorable than I-Mab.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
I-Mab	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.33
CervoMed	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89

Which has more risk and volatility, IMAB or CRVO?

I-Mab has a beta of 1.4, suggesting that its share price is 40% more volatile than the S&P 500. Comparatively, CervoMed has a beta of -0.75, suggesting that its share price is 175% less volatile than the S&P 500.

Summary

I-Mab and CervoMed tied by winning 7 of the 14 factors compared between the two stocks.